抗人活化蛋白C抗体在临床前模型中预防先天性凝血因子缺乏的安全性与有效性
研究基于鼠源抗体HAPC1573构建人源化嵌合抗体SR604,选择性阻断人活化蛋白C(APC)的抗凝活性。体外实验中SR604阻断多种凝血因子缺乏血浆中APC抗凝活性的亲和力约为HAPC1573的60倍;在表达人APC的血友病A和B小鼠尾出血及膝损伤模型中显示预防和治疗效果,未干扰APC的细胞保护及内皮屏障功能,未见明显毒性;食蟹猴皮下注射生物利用度为106%。
要点
- SR604选择性阻断人APC抗凝活性,体外亲和力约为鼠源前体HAPC1573的60倍。
- 在表达人APC的血友病A和B小鼠模型中,SR604显示预防和治疗效果。
- 食蟹猴皮下注射SR604的生物利用度为106%,未见明显毒性。
核心结论
- SR604有望成为用于包括血友病A和B在内的先天性凝血因子缺乏患者的安全有效的治疗和/或预防药物,且具有延长的半衰期。
研究设计与样本
- 临床前研究:基于已发表的鼠源抗体HAPC1573构建人源化嵌合抗体SR604,在体外、血友病A和B人源化小鼠模型及食蟹猴中进行评价。
主要发现
- SR604在体外有效阻断多种凝血因子缺乏人血浆中APC的抗凝活性,亲和力约为HAPC1573的60倍。
- SR604在表达人APC的血友病A和B小鼠尾出血和膝损伤模型中表现出预防和治疗效果。
- SR604不干扰APC的细胞保护和内皮屏障功能,在人源化血友病小鼠中未见明显毒性效应。
- 药代动力学研究显示食蟹猴皮下注射SR604的生物利用度为106%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rebalance of coagulation and anticoagulation to achieve a hemostatic effect has recently gained attention as an alternative therapeutic strategy for hemophilia. We engineered a humanized chimeric antibody, SR604, based on a previously published murine antibody, HAPC1573, which selectively blocks the anticoagulant activity of human activated protein C (APC). SR604 effectively blocked the anticoagulation activities of APC in human plasma deficient in various coagulation factors in vitro with affinities ∼60 times greater than that of HAPC1573. SR604 exhibited prophylactic and therapeutic efficacy in the tail-bleeding and knee-injury models of hemophilia A and B mice expressing human APC (humanized hemophilic mice). SR604 did not interfere with the cytoprotection and endothelial barrier function of APC, nor were there obvious toxicity effects in humanized hemophilic mice. Pharmacokinetic study showed a high bioavailability (106%) of subcutaneously injected SR604 in cynomolgus monkeys. These results demonstrate that SR604 is expected to be a safe and effective therapeutic and/or prophylactic agent with a prolonged half-life for patients with congenital factor deficiencies including hemophilia A and B.
引用
- Jiang M, Yang F, Jiang Y, et al. Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models. Blood. 2023. PMID: 37294924. doi:10.1182/blood.2023020005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。